Inspire Investing LLC Buys New Holdings in Sarepta Therapeutics, Inc. $SRPT

Key Points

• Inspire Investing LLC has acquired a new stake of 15,147 shares in Sarepta Therapeutics, valued at approximately $967,000, indicating growing institutional interest in the biotechnology firm.
• Despite recent institutional investments, Sarepta Therapeutics faces mixed analyst sentiments, with ratings ranging from "Buy" to "Sell" and a significant reduction in price objectives from previous highs.
• The company reported a 68.4% increase in quarterly revenue year-over-year, reaching $611.09 million, significantly beating analysts' expectations.

Inspire Investing LLC bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,147 shares of the biotechnology company's stock, valued at approximately $967,000.

Other institutional investors also recently bought and sold shares of the company. Byrne Asset Management LLC purchased a new stake in Sarepta Therapeutics during the 1st quarter valued at about $30,000. Center for Financial Planning Inc. purchased a new stake in Sarepta Therapeutics during the 1st quarter valued at about $31,000. Ancora Advisors LLC boosted its holdings in Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 300 shares during the period. Pandora Wealth Inc. purchased a new stake in Sarepta Therapeutics during the 1st quarter valued at about $45,000. Finally, Brooklyn Investment Group boosted its holdings in Sarepta Therapeutics by 450.4% during the 1st quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company's stock valued at $46,000 after acquiring an additional 590 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SRPT has been the subject of several analyst reports. HC Wainwright restated a "sell" rating on shares of Sarepta Therapeutics in a report on Monday, August 25th. Wolfe Research initiated coverage on Sarepta Therapeutics in a report on Tuesday, June 17th. They set a "peer perform" rating for the company. Leerink Partnrs cut Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. Mizuho reiterated a "neutral" rating and issued a $14.00 price objective (down previously from $40.00) on shares of Sarepta Therapeutics in a report on Monday, July 21st. Finally, Bank of America increased their price objective on Sarepta Therapeutics to $17.00 and gave the stock an "underperform" rating in a report on Wednesday, August 20th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have given a Sell rating to the company's stock. According to data from MarketBeat, Sarepta Therapeutics has an average rating of "Hold" and an average target price of $42.36.

Sarepta Therapeutics Trading Down 2.9%

NASDAQ SRPT opened at $17.39 on Friday. The stock has a market cap of $1.70 billion, a P/E ratio of -19.99 and a beta of 0.49. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The stock has a 50 day simple moving average of $17.75 and a two-hundred day simple moving average of $41.28. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $0.89 by $1.13. The company had revenue of $611.09 million during the quarter, compared to analysts' expectations of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The firm's revenue for the quarter was up 68.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.07 EPS. On average, analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.